Xueshuantongmai drug, preparation method and content determination method

A thrombus and drug technology, which is applied in the fields of thrombus dredging drugs, treatment of cerebral thrombus, preparation methods and content determination, and can solve the problems that traditional drugs have not achieved satisfactory results and the like.

Active Publication Date: 2021-12-31
唐宏
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the scientific community has made great progress in the understanding of these diseases, the therapeutic effects of traditional medicines have not achieved satisfactory results

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Xueshuantongmai drug, preparation method and content determination method
  • Xueshuantongmai drug, preparation method and content determination method
  • Xueshuantongmai drug, preparation method and content determination method

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] Xueshuan Tongmai Capsules, its medicinal active ingredients are made of the following raw materials in parts by weight: Astragalus 30g, Earthworm 10g, Wood Beetle 10g, Leech 10g, Peach Kernel 20g, Chuanxiong 15g, Tangerine 15g, Angelica 15g, Spatholobus Spatholobus 15g. Determine the starch as the auxiliary material, the ratio of the extract to the auxiliary material is 6:4, use 85% ethanol as the wetting agent, knead into a ball, mechanically press through a 20-mesh sieve for granulation, dry at 40°C, and then pass through a 40-mesh sieve to remove dust , get granules, and fill capsules.

experiment example 1

[0049] Determination of the preparation process, curative effect and content identification of Xueshuan Tongmai Capsules

[0050] 1.1 Experimental materials

[0051] 1.1.1 Instruments and equipment, see Table 1

[0052]

[0053] 1.1.2 Reagents, see Table 2

[0054]

[0055] 1.1.3 Medicinal materials

[0056] The standards of medicinal materials in this experiment were selected according to the items of medicinal materials in the 2015 edition of the Chinese Pharmacopoeia.

[0057] 1.1.4 Liquid phase conditions

[0058] Astragaloside IV: InertSustain C18 column (5μm, 4.6×250mm) with octadecylsilane bonded silica gel as filler, acetonitrile-water (35:65) as mobile phase, evaporative light scattering detector, flow rate is 1.0ml / min, column temperature 40°C, drift tube temperature 40°C.

[0059] Ferulic acid: InertSustain C18 column (5μm, 4.6×250mm) with octadecylsilane bonded silica gel as filler, acetonitrile-water (17:83) as mobile phase, detection wavelength 316nm, ...

experiment example 2

[0128] Xueshuan Tongmai Capsule Containing Serum on H 2 o 2 Protective effect of induced oxidative damage in HUVEC cells

[0129] 3.1 Experimental materials

[0130] 3.1.1 Cells

[0131] Human umbilical vein endothelial cell line (HUVEC) was purchased from the Kunming Cell Bank of the Chinese Academy of Sciences (Kunming Cell Bank No.: KCB2012087YJ).

[0132] 3.1.2 Experimental animals

[0133] 30 male SD rats, 8 weeks old, weighing 165-175g, were purchased from Beijing Huafukang Biotechnology Co., Ltd., and the quality inspection was carried out by the Jilin Provincial Laboratory Animal Quality Inspection Center. License number: SCXK (Ji)-2016 -0003. Five animals per cage were reared in separate cages, the culture temperature was 20±2°C, and common animal feed was used for feeding.

[0134]

[0135]

[0136] 3.2 Experimental method

[0137] 3.2.1 Preparation of serum containing Xueshuan Tongmai Capsules

[0138] Thirty 8-week-old male SD rats were randomly divid...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
heightaaaaaaaaaa
Login to view more

Abstract

The invention relates to the field of traditional Chinese medicine, that is, a thrombus-tongmai medicine, a preparation method and a content determination method, which are used for treating cerebral thrombosis. It is made from astragalus, earthworm, ground beetle, leech, peach kernel, chuanxiong, tangerine, angelica, and spatholobus according to the specified amount, and has a good effect on treating cardiovascular and cerebrovascular diseases. The experimental results showed that the blood serum containing Xueshuan Tongmai Capsules could significantly increase H 2 o 2 (hydrogen peroxide) treated HUVEC cell viability, decreased LDH, MDA, ROS content, and increased GSH (glutathione), NO (nitric oxide), SOD (superoxide dismutase) content, suggesting that Xueshuantong The medicated serum in Mai capsule has the ability to protect vascular endothelial cells from oxidative damage. Xueshuan Tongmai Capsules can significantly inhibit the formation of thrombus in SD rats in vivo and in vitro, and the inhibitory effect is enhanced with the increase of the dose, and the effect of the high-dose group is better than that of the low-dose group.

Description

technical field [0001] The invention relates to the field of traditional Chinese medicines, that is, a medicine for dredging blood clots, a preparation method and a content determination method, which are used for treating cerebral thrombosis. Background technique [0002] In the prior art, cardiovascular and cerebrovascular diseases are a general term for cardiovascular and cerebrovascular diseases, and generally refer to the occurrence of heart, brain and systemic tissues due to factors such as hypertension, atherosclerosis, hyperlipidemia, and blood viscosity. hemorrhagic or ischemic disease. Cardiovascular and cerebrovascular diseases are the leading cause of death worldwide. According to the current epidemiological data, it is estimated that by 2020, although the sequence of diseases leading to death will undergo major changes, coronary heart disease and cerebral hemorrhage will still be the first and second leading causes of death in humans. Although the scientific c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K36/752A61K9/48A61K47/36A61P9/10A61P7/02G01N30/02G01N30/86A61K35/62A61K35/64
CPCA61K36/481A61K35/62A61K35/64A61K36/736A61K36/236A61K36/752A61K36/232A61K36/486A61K9/1652A61P9/10A61P7/02G01N30/02G01N30/8675A61K2236/333A61K2236/39A61K2236/51A61K2300/00
Inventor 唐宏
Owner 唐宏
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products